Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDabrdn Life Sciences Investors Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 09/30/2025 | Q4 2025 | N/A | $4.60 | N/A | N/A | $68.19 M |
| 03/30/2025 | Q2 2025 | N/A | -$1.64 | N/A | N/A | $18.20 M |
| 09/30/2024 | Q4 2024 | N/A | $1.22 | N/A | N/A | $1.91 M |
| 03/30/2024 | Q2 2024 | N/A | $1.84 | N/A | N/A | $2.07 M |
| 09/29/2023 | Q4 2023 | N/A | -$0.43 | N/A | N/A | $29.56 M |
| 03/31/2023 | Q2 2023 | N/A | $1.29 | N/A | N/A | $1.93 M |
| 09/30/2022 | Q4 2022 | N/A | -$1.10 | N/A | N/A | $21.69 M |
| 03/31/2022 | Q2 2022 | N/A | -$3.03 | N/A | N/A | $10.17 M |
| 09/30/2021 | Q4 2021 | N/A | $1.34 | N/A | N/A | $15.98 M |
| 03/31/2021 | Q2 2021 | N/A | $1.30 | N/A | N/A | $29.03 M |
| 09/30/2020 | Q4 2020 | N/A | $3.91 | N/A | N/A | $16.50 M |
| 03/30/2020 | Q2 2020 | N/A | $1.29 | N/A | N/A | $22.57 M |
| 09/30/2019 | Q4 2019 | N/A | -$1.33 | N/A | N/A | $1.31 M |
| 03/31/2019 | Q2 2019 | N/A | -$1.72 | N/A | N/A | $1.13 M |
| 09/30/2018 | Q4 2018 | N/A | $2.12 | N/A | N/A | $988.76 K |
| 03/31/2018 | Q2 2018 | N/A | -$0.90 | N/A | N/A | $997.06 K |
| 09/29/2017 | Q4 2017 | N/A | $0.00 | N/A | N/A | $891 |
| 03/31/2017 | Q2 2017 | N/A | $1.26 | N/A | N/A | $791 |
| 09/29/2016 | Q4 2016 | N/A | $2.76 | N/A | N/A | $722 |
| 03/31/2016 | Q2 2016 | N/A | -$3.44 | N/A | N/A | $716 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
abrdn Life Sciences Investors Earnings: FAQ's
The conference call for abrdn Life Sciences Investors's latest earnings report can be listened to online.
The conference call transcript for abrdn Life Sciences Investors's latest earnings report can be read online.
abrdn Life Sciences Investors (:HQL) has a recorded annual revenue of $86.39 M.
abrdn Life Sciences Investors (:HQL) has a recorded net income of $85.59 M.abrdn Life Sciences Investors has generated $2.96 earnings per share over the last four quarters.
abrdn Life Sciences Investors (:HQL) has a price-to-earnings ratio of 5.9 and price/earnings-to-growth ratio is 0.01.